Loading
Vera Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 Dec 2025.
Vera Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Vera Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 12 insiders have disclosed 45 filings since 18 October 2025.
Both sides are active: 1 purchase worth €214k and 24 sales worth €6.6M, from 1 insider and 8 insiders respectively. No amount is published for 2 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Fordyce Marshall filed the largest sale, €1.2M, on 9 July 2026, which represents 0.057% of the company's market value. The buyers include 1 senior executive.
The last insider purchase was made public on 15 December 2025, 307 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 45 filings here. Over the whole record (from 2021), the tally stands at 27 purchases and 39 sales. The 10-K for the year ended 31 December 2025 shows -299.6 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
145
Thresholds
n/a
Buy Volume
€35M
27 ops. · all time
Sell Volume
€27M
39 ops. · all time
Who traded when
BuySaleMarshall Fordyce21 sales
Enright Patrick G2 buys
Joseph R. Young2 sales
Brenner Robert1 sale
Carter Jason S1 sale
Grant Sean1 sale
+3 other insiders
Since the insiders bought
- -17.1%Entry US$48.30 · Close at T+90 US$40.05
- -6.7%Entry US$39.15 · Close at T+365 US$36.54
- +99.6%Entry US$17.48 · Close at T+365 US$34.89
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Vera Therapeutics, Inc. Strong Buy (bullish), based on 15 analysts. Average price target: US$74.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$26.74
Analyst consensus
15 analystsStrong buy
US$34.00Target US$74.20(+177%)US$100.00
Income statement
EBITDA-US$291.6M
Net income-US$299.6M0.0% margin
Valuation
PER (forward)-6.3x
P/Book4.7x
Beta1.05
Balance sheet & cash
Market capUS$1.9B
Total debtUS$77.3M
Free Cash Flow-US$241.7M
Debt / Equity19%
Profitability & ownership
ROE-91.8%
ROA-46.8%
% insiders1.0%
% institutions118.1%
Last declaration on 17 September 2026
Declarations145 total
18,500 shares@ US$37.000.028% mcap8.2% of flowClass A Common StockSEC:0001859453-26-000015:1
18,500 shares@ US$2.89680.0022% mcap0.6% of flowClass A Common StockSEC:0001859453-26-000015:0
5,000 shares@ US$3.93960.0008% mcap2.0% of flowClass A Common StockSEC:0001861684-26-000006:0
18,500 shares@ US$2.89680.0022% mcap0.6% of flowClass A Common StockSEC:0001859453-26-000014:0
18,500 shares@ US$35.11580.027% mcap7.7% of flowClass A Common StockSEC:0001859453-26-000014:1
18,500 shares@ US$2.89680.0024% mcap0.6% of flowClass A Common StockSEC:0001859453-26-000012:0
18,412 shares@ US$37.93110.031% mcap8.5% of flowClass A Common StockSEC:0001859453-26-000012:1
88 shares@ US$38.430.0002% mcap0.0% of flowClass A Common StockSEC:0001859453-26-000012:2
18,500 shares@ US$2.89680.6% of flowClass A Common StockSEC:0001859453-26-000011:0
14,219 shares@ US$36.63966.1% of flowClass A Common StockSEC:0001859453-26-000011:1
4,281 shares@ US$37.08681.9% of flowClass A Common StockSEC:0001859453-26-000011:2
46,250 shares@ US$2.89680.0056% mcap1.6% of flowClass A Common StockSEC:0001859453-26-000013:0
44,987 shares0Class A Common StockSEC:0002145711-26-000002:0
32,550 shares@ US$42.07360.057% mcap16.5% of flowClass A Common StockSEC:0001859453-26-000010:1
10,500 shares@ US$42.85780.019% mcap5.4% of flowClass A Common StockSEC:0001859453-26-000010:2
2,200 shares@ US$43.59470.0040% mcap1.2% of flowClass A Common StockSEC:0001859453-26-000010:3
1,000 shares@ US$40.77620.0017% mcap0.5% of flowClass A Common StockSEC:0001859453-26-000010:0
18,412 sharesClass A Common StockSEC:0001859453-26-000008:0
88 sharesClass A Common StockSEC:0001859453-26-000008:1
74,000 shares@ US$38.430.098% mcap100.0% of flowCommonSEC144:0001950047-26-006433
14,130 shares@ US$43.66490.020% mcap7.2% of flowClass A Common StockSEC:0001859453-26-000006:0
7,921 shares@ US$44.57840.012% mcap4.1% of flowClass A Common StockSEC:0001859453-26-000006:1
900 shares@ US$45.51140.0013% mcap0.5% of flowClass A Common StockSEC:0001859453-26-000006:2
42,403 shares0Class A Common StockSEC:0001614568-26-000008:0
10,000 shares@ US$3.93964.0% of flowClass A Common StockSEC:0001861684-26-000005:0
25 of 145 declarations
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ under the ticker VERA. It is headquartered in Brisbane, California, United States. For French, Belgian, and Swiss investors, Vera is best viewed as a late-stage clinical biotech transitioning toward first commercialization, with no meaningful product revenue to date and a value proposition tied to clinical execution, regulatory milestones, and eventual market adoption.
The company was originally founded under a different name and was renamed Vera Therapeutics in 2020. Since then, it has focused on serious immunological diseases, with a strong emphasis on autoimmune kidney disorders. Its lead strategic target is IgA nephropathy (IgAN), also known as Berger’s disease, a chronic kidney disease that can progressively impair renal function and ultimately lead to kidney failure in some patients. Vera’s stated mission is to change the standard of care by addressing the immune drivers of disease rather than only managing downstream symptoms.
Read moreShow less
Vera’s principal asset is atacicept, a self-administered once-weekly subcutaneous fusion protein that blocks both BAFF and APRIL, two biologic pathways involved in B-cell and plasma-cell activation and autoantibody production. In investor terms, atacicept is the company’s key value driver and the asset most likely to determine whether Vera evolves from a development-stage biotech into a commercial specialty pharmaceutical company. The firm is also advancing MAU868, a monoclonal antibody designed to neutralize BK virus infection, an important complication in kidney transplant and other immunosuppressed settings.
From a competitive standpoint, Vera operates in a highly selective niche where success depends on high-quality clinical data, regulatory timing, and the ability to translate late-stage trial results into a commercial launch. In IgAN, the company strengthened its profile in 2025 with positive Phase 3 ORIGIN data, which were presented at ASN Kidney Week and published in the New England Journal of Medicine. More recently, in January 2026, the U.S. FDA granted priority review to the BLA for atacicept in adult IgAN, with a PDUFA target action date of July 7, 2026. In its May 2026 business update, Vera said it remained on track for a U.S. commercial launch in mid-2026, pending approval, and highlighted a balance sheet expected to fund operations beyond potential approval and launch.
Geographically, Vera remains primarily U.S.-focused, with corporate operations centered in California and a near-term commercialization strategy aimed at the United States market. For European investors, the stock represents a classic NASDAQ biotech catalyst story: concentrated pipeline exposure, significant binary regulatory risk, and potentially meaningful upside if atacicept clears FDA review and gains traction in IgAN.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
